Advanced Search

Submit Manuscript

Volume 32, No 1, Jan 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 1, January 2022: 103-106   |  Open Access

LETTERS TO THE EDITOR

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

Jingwen Ai1,† , Haocheng Zhang1,† , Qiran Zhang1,† , Yi Zhang1,† , Ke Lin1 , Zhangfan Fu1 , Jieyu Song1 , Yuanhan Zhao1 , Mingxiang Fan1 , Hongyu Wang1 , Chao Qiu1 , Yang Zhou1 , Wenhong Zhang1,2,3,*

1Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
2National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
3Key Laboratory of Medical Molecular Virology (MOE/MOH) Shanghai Medical College, Fudan University, Shanghai, China
These authors contributed equally: Jingwen Ai, Haocheng Zhang, Qiran Zhang, Yi Zhang
Correspondence: Wenhong Zhang(zhangwenhong@fudan.edu.cn)

Dear Editor,

As of October, 2021, SARS-CoV-2 has infected more than 230 million people; promoting roll-out vaccinations could help build herd immunity for the pandemic. However, the waning of antibody in magnitude and decreased protective efficacy in multiple types of vaccines have been reported. Along with the circulating variants to some degree escaping from immune response, these led to the argument of further booster vaccination in recipients who have previously received “priming” vaccination. Recent studies reported that a third homologous dose showed a satisfying safety profile and higher immune response, including BNT162b2 mRNA vaccine, CoronaVac inactivated vaccine and BBIBP-CorV vaccine.1,2,3 Additionally, heterologous prime-boost vaccination of ChAdOx1 nCoV-19 followed by BNT162b2 induced a higher neutralizing activity compared to two homologous doses of ChAdOx1 nCoV-19.4 Until now, the effect of heterologous vaccination of recombinant protein subunit vaccine primed with two doses of inactivated vaccines has not been evaluated, and data along this line could provide further evidence in establishing future global boosting strategies.



https://doi.org/10.1038/s41422-021-00590-x

FULL TEXT | PDF

Browse 534